Innovex International, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Innovex International, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $424.06M | Jul 8, 2024 |
| FY2023 | Dec 31, 2022 | $361.92M | Jul 8, 2024 |
| FY2023 | Dec 31, 2021 | $322.45M | Jul 8, 2024 |
| FY2020 | Dec 31, 2020 | $87.23M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $91.30M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $90.45M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $96.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $108.45M | Feb 27, 2020 |
| FY2020 | Sep 30, 2019 | $108.23M | Feb 25, 2021 |
| FY2020 | Jun 30, 2019 | $103.81M | Feb 25, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $978.25M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $660.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $555.54M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $467.19M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $287.90M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $334.41M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $375.30M | Feb 25, 2021 |
| FY2018 | Dec 31, 2018 | $337.47M | Feb 27, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $23.10M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $24.08M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $23.51M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $24.58M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $32.71M | Feb 27, 2020 |
| FY2020 | Sep 30, 2019 | $32.20M | Feb 25, 2021 |
| FY2020 | Jun 30, 2019 | $29.94M | Feb 25, 2021 |
| FY2020 | Mar 31, 2019 | $24.94M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $23.90M | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | $22.14M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $140.33M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $73.93M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $63.28M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($128.49M) | Jul 8, 2024 |
| FY2020 | Dec 31, 2020 | ($11.25M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $14.33M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($14.14M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($19.70M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $7.40M | Feb 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.63M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $49.08M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $97.28M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $75.84M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($125.34M) | Jul 8, 2024 |
| FY2020 | Dec 31, 2020 | ($11.63M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($2.10M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($7.51M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($42.32M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $6.06M | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.70M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.70M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $3.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $2.50M | Mar 3, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.79M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $116.18M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $72.80M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $59.19M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $115.04M | Jul 8, 2024 |
| FY2022 | Dec 31, 2020 | $95.06M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $98.41M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $102.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $113.59M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $53.25M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.91M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $93.44M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $75.86M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($5.81M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $38.43M | Jul 8, 2024 |
| FY2022 | Dec 31, 2020 | ($21.09M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $14.68M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $45.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $107.99M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $246.52M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $32.63M | Jul 8, 2024 |
| FY2023 | Dec 31, 2022 | $18.87M | Jul 8, 2024 |
| FY2023 | Dec 31, 2021 | $9.99M | Jul 8, 2024 |
| FY2022 | Dec 31, 2020 | $11.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $11.50M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $32.06M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $27.62M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $25.76M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $27.08M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $42.55M | Feb 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.27B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.20B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $475.30M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $969.95M | Jul 8, 2024 |
| FY2023 | Dec 31, 2021 | $1.01B | Jul 8, 2024 |
| FY2021 | Dec 31, 2020 | $1.15B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.21B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.19B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.40B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $1.46B | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.61M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $239.33M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $146.38M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $97.60M | Jul 8, 2024 |
| FY2022 | Dec 31, 2021 | $113.32M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $109.64M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $115.86M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $96.35M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $105.34M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $104.98M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $958.16M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $328.92M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $251.28M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $180.55M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $1.04B | Jul 8, 2024 |
| FY2022 | Dec 31, 2019 | $1.09B | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $1.10B | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | $1.29B | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $1.36B | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.72M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $60.18M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $23.93M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $23.93M | Mar 3, 2025 |
| FY2020 | Dec 31, 2019 | $7.95M | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $7.71M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $47.62M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $34.37M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 28, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.27M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $211.25M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $145.91M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $950.17M | Jul 8, 2024 |
| FY2022 | Dec 31, 2021 | $973.09M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.13B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.18B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.21B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.40B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $1.50B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $187.32M | Jul 8, 2024 |
| FY2023 | Dec 31, 2022 | $259.41M | Jul 8, 2024 |
| FY2022 | Dec 31, 2021 | $355.45M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $345.96M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $398.95M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $418.10M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $493.18M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $423.50M | Feb 27, 2019 |
| FY2018 | Dec 31, 2015 | $381.34M | Feb 27, 2019 |
| FY2017 | Dec 31, 2014 | $298.71M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $25.43M | Mar 3, 2025 |
| FY2012 | Dec 31, 2011 | $57.0K | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $326.0K | Feb 27, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Jul 8, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Jul 8, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 69.08M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 69.18M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 30.93M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 34.16M | Jul 8, 2024 |
| FY2022 | Dec 31, 2021 | 34.77M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 35.42M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 35.86M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 36.26M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 38.13M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 37.80M | Feb 27, 2018 |